The fund held 1.0803 fractional shares of IONS and sold them at 58.45 during the regular session. This shows that when it is important to be able to sell shares overnight, it is better to use whole-share lots that are affordable, otherwise it is better not to buy. The loss from buying to selling should not be labeled as a loss due to poor timing without comparing to actual price quotes that could have been used to buy or sell.
Technical
Catalyst run-upstrade #42026-09-04 20:54
The stock IONS was bought with a potential reward of 1.40 times the potential risk, which is the ratio of the possible gain to the possible loss. This was based on an entry price of 60.16, a stop loss at 56, and a target price of 66. In the future, the fund manager will require a reward to risk ratio of at least 1.5, which means the potential gain must be at least 1.5 times the potential loss, using a target price that is reasonably attainable. The stock was sold at a loss of 2.84%, but this sale does not provide a fair test of the signal that triggered the initial buy, known as the catalyst signal.
Technical
Catalyst run-ups2026-09-04 02:54
FDA target action dates are deadlines, not guaranteed event dates: IONS was approved 19 days early and fell 5.3% that day. A pre-PDUFA exit, which means stopping a trade before the FDA makes a decision, does not remove early-action or sell-the-news risk.
Psyche
Catalyst run-upstrade #22026-09-04 02:54
Do not focus only on the named PDUFA, which is a Food and Drug Administration decision date, and treat other pipeline events as background. A single-catalyst narrative hid the larger Aspire readout; require a written company-wide event inventory before entry.
Order placement
Catalyst run-upstrade #22026-09-04 02:54
A $24 stop did not limit the risk for RARE, which is a type of order to sell a stock when it falls to a certain price, in this case $24. The stock was actually sold for $13.99, which is 41.7% below the stop price, after a sudden price jump overnight, known as a binary gap. This means that the size of the investment in biotech stocks should be determined by the potential loss from a sudden price jump, not by how far the stop price is from the current price. Additionally, no investment should be made when there is a possibility of another sudden price jump, known as a binary window, overlapping with the current one.
Technical
Catalyst run-upstrade #22026-09-04 02:54
Before investing in any biotech company, it is essential to identify and plan for every significant event, such as clinical trials and regulatory decisions, that may affect the company's stock through to the planned time of selling the stock. For example, the stock price of RARE fell 45.9% because the expected results of the GTX-102 clinical trial in September or October happened at the same time as the period leading up to the UX111 PDUFA decision, which is a regulatory review, and this overlap had a negative impact on the stock price.